Shanghai Junshi Biosciences (HKG:1877, SHA:688180) received a Drug Registration Certificate for toripalimab after China's National Medical Products Administration approved a supplemental new drug application.

The approval comes for the use of the drug as the first-line treatment for unresectable or metastatic melanoma, an April 25 Hong Kong bourse filing said.

This marks the approval of toripalimab's 12th indication in the Chinese mainland.